Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pul...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: www.mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

jlonards Oct. 4 at 8:08 PM

$MNKD FDKP for the WIN FDKP stands for Fumaryl Diketopiperazine, an FDA-approved, inert excipient used as a carrier in drug delivery systems like MannKind Corporation's Technosphere® technology. It forms microparticles that can encapsulate drugs, such as insulin for Afrezza®, for inhalation into the lungs. FDKP is not metabolized and is safely excreted via the kidneys, making it a safe and versatile component for systemic drug delivery through pulmonary administration. Key Features and Uses of FDKP Drug Delivery System: FDKP is the key component of the Technosphere® drug delivery system. Pulmonary Administration: It enables drugs to be delivered directly into the lungs via a dry powder inhaler (DPI). Microparticle Formation: FDKP self-assembles into microparticles through hydrogen bonding under acidic conditions. Drug Encapsulation: These microparticles can then adsorb or microencapsulate therapeutic agents, such as human insulin.

2 · Reply

clan Oct. 4 at 6:16 PM

$MNKD will be $50/share in 2028. - - Change My Mind - -

0 · Reply

WallStreetBuyDip Oct. 4 at 1:04 PM

$MNKD Massive 1.8x volume spike compared to average with 5.1M shares traded. Price range from $3.42 to $7.44 recently. Smart move to wait for a lower H% before considering entry.

0 · Reply

stevemano Oct. 4 at 1:02 PM

$MNKD

0 · Reply

masspd Oct. 4 at 11:49 AM

$MNKD why will the stock price go up - some ask??? Why now??? Q4 revenue is projected at ~$80M, with a 2026 run rate of ~$320M. Adding 2026 forecast revenue from FUROSCIX of $110–120M brings the total to $430–440M in 2026, excluding potential contributions from pediatric Afrezza, growth in adult Afrezza, and additional DPI opportunities. Maybe 101 towards the end of 2026 and 201 in 27/28. This isn’t your grandfather’s Mannkind company!!! 😂 LFG!

1 · Reply

clan Oct. 4 at 9:37 AM

$MNKD The pieces to the Mannkind puzzle are coming together ... and it's makin' fer a pretty nice lookin' picture!🧩💲🧩💲 $SCPH $UTHR $BX

1 · Reply

JohnB72 Oct. 4 at 9:09 AM

$MNKD is our time finally here? It’s been “out year is next year” since 2015.

0 · Reply

The_Owl_ Oct. 4 at 8:11 AM

$MNKD line in the sand = High Gamma at $6.00 (0.8452), if crossed: 10/17/25 Expected Move Upper Price = $6.22 highest Open Interest (29,630 OI in 01/16/26 Expiration) = $6.99 = also aligns with known technical resistance and the 11/21/25 Expected Move Upper Price of $6.69

1 · Reply

Kuka Oct. 4 at 4:58 AM

$MNKD I am excited for all MNKD Longs but more excited for the Guys like me (Poor/Retirees)....the folks buying 80,000+ shares will be fine whatever happens here but for the guys like me ..this will be life changing. This is going to be an exciting next 8 months. :)

2 · Reply

whiskyqueen Oct. 4 at 12:46 AM

$MNKD BBBBBBBB..

0 · Reply

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 16, 2025, 12:17 PM EDT - 18 days ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Sep 10, 2025, 7:30 PM EDT - 23 days ago

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 7, 2025, 9:55 PM EDT - 26 days ago

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:28 PM EDT - 26 days ago

MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:05 PM EDT - 5 weeks ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 5 weeks ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 25, 2025, 1:57 PM EDT - 5 weeks ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 25, 2025, 1:36 PM EDT - 5 weeks ago

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

Aug 6, 2025, 5:20 PM EDT - 2 months ago

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 2 months ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 2 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 2 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 2 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 4 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 4 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 4 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 4 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 8, 2025, 11:34 AM EDT - 5 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 5 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 5 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 6 months ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 7 months ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 7 months ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 7 months ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 7 months ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 8 months ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 3, 2025, 9:20 AM EST - 8 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MSTR SKE SKYE AMSC

Jan 6, 2025, 4:30 PM EST - 9 months ago

MannKind Expands Executive Leadership Team

Dec 17, 2024, 7:16 AM EST - 10 months ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 16, 2024, 6:05 AM EST - 10 months ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 10 months ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 8:30 PM EST - 11 months ago

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:02 PM EST - 11 months ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 11 months ago

MannKind to Present at 2024 UBS Healthcare Conference

Nov 4, 2024, 6:05 AM EST - 11 months ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Oct 31, 2024, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 30, 2024, 9:00 PM EDT - 1 year ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Oct 3, 2024, 8:00 AM EDT - 1 year ago

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Sep 30, 2024, 6:00 AM EDT - 1 year ago

More Adults With Type 1 Diabetes Achieved A1C Goal (

Sep 18, 2024, 6:15 AM EDT - 1 year ago

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Sep 10, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at Upcoming Conferences

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

Aug 7, 2024, 12:29 PM EDT - 1 year ago

MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 8:00 AM EDT - 1 year ago

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

Jul 31, 2024, 6:30 AM EDT - 1 year ago

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

Jul 30, 2024, 4:30 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

Jun 22, 2024, 8:00 AM EDT - 1 year ago

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions

Jun 5, 2024, 6:45 AM EDT - 1 year ago

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

jlonards Oct. 4 at 8:08 PM

2 · Reply

clan Oct. 4 at 6:16 PM

$MNKD will be $50/share in 2028. - - Change My Mind - -

0 · Reply

WallStreetBuyDip Oct. 4 at 1:04 PM

$MNKD Massive 1.8x volume spike compared to average with 5.1M shares traded. Price range from $3.42 to $7.44 recently. Smart move to wait for a lower H% before considering entry.

0 · Reply

stevemano Oct. 4 at 1:02 PM

$MNKD

0 · Reply

masspd Oct. 4 at 11:49 AM

1 · Reply

clan Oct. 4 at 9:37 AM

$MNKD The pieces to the Mannkind puzzle are coming together ... and it's makin' fer a pretty nice lookin' picture!🧩💲🧩💲 $SCPH $UTHR $BX

1 · Reply

JohnB72 Oct. 4 at 9:09 AM

$MNKD is our time finally here? It’s been “out year is next year” since 2015.

0 · Reply

The_Owl_ Oct. 4 at 8:11 AM

1 · Reply

Kuka Oct. 4 at 4:58 AM

2 · Reply

whiskyqueen Oct. 4 at 12:46 AM

$MNKD BBBBBBBB..

0 · Reply

Kuka Oct. 4 at 12:27 AM

$MNKD

0 · Reply

SS115 Oct. 4 at 12:14 AM

$MNKD Schwab is posting an interesting EPS for next earnings. 😎

1 · Reply

masspd Oct. 3 at 10:15 PM

$MNKD LFG… it’s finally happening. Revenue and Profit is the trump card when it come to business!!! The meaning of "trump card" comes from trick-taking card games, where a trump is a powerful card that can beat any card of another suit. Metaphorically, a "trump card" is any resource or advantage held in reserve to be used at a crucial moment to secure a victory.

2 · Reply

PNW_MBA Oct. 3 at 10:12 PM

$MNKD Kudos!

0 · Reply

Plergh Oct. 3 at 10:11 PM

$MNKD I liked that candle, too.

0 · Reply

Golf365 Oct. 3 at 9:41 PM

$MNKD Looking forward to the day when Mannkind has a pps upwards of Liquidia. 💪 🎰

0 · Reply

ZeroDog Oct. 3 at 9:02 PM

$MNKD Friday afternoon geography update

1 · Reply

Arielsquarefour Oct. 3 at 8:12 PM

$MNKD I do have a question and forgive me if it seems stupid as medical trials have so many ways they measure success or stages it confuses me. Is the upcoming submission for pediatrics mean that they will be cleared to sell Afrezza for children next week, or is this just part of the peds trial that is scheduled to end middle of next year.

1 · Reply

pierrules Oct. 3 at 8:00 PM

$MNKD Have a Great weekend folks 😊 its always good to end the week with a nice...

0 · Reply

Arielsquarefour Oct. 3 at 7:51 PM

$MNKD I am so glad to see this finally getting respect and its feet on the ground. So many positives going forward into 2026. Could be easily over 100 a share if only two of their projects get going.

2 · Reply

TwitsNelson123 Oct. 3 at 7:51 PM

$MNKD

0 · Reply

jlonards Oct. 3 at 7:26 PM

$MNKD

0 · Reply

Market Cap	1.68B
Revenue (ttm)	285.50M
Net Income (ttm)	27.59M
EPS (ttm)	N/A
PE Ratio	48.91
Forward PE	59.78
Profit Margin	9.66%
Debt to Equity Ratio	-2.54

Volume	5,126,900
Avg Vol	4,470,292
Day's Range	N/A - N/A
Shares Out	306.83M
Stochastic %K	81%
Beta	1.08
Analysts	Strong Sell
Price Target	$10.12